SparX Group is a biotech firm that develops innovative anticancer biologics through bispecific antibodies and drug conjugates.
SparX Group has raised $30.0M in total funding. The most recent round was Series B. The last funding was announced in December 2021.
SparX Group's investors include Highlight Capital, Sangel Capital, Rotating Boulder Fund, Bosi Gongchuang.
SparX Group is headquartered in Grand Cayman, Cayman Islands.
SparX Group is a biotech firm that develops innovative anticancer biologics through bispecific antibodies and drug conjugates.
SparX Group is at the Series B stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"SparX Group — Funding & Investors." VCBacked, December 31, 2021, https://www.vcbacked.co/company/sparx-group. Accessed September 30, 2026.
VCBacked. (2021). SparX Group — Funding & Investors. Retrieved September 30, 2026, from https://www.vcbacked.co/company/sparx-group
{{cite web |title=SparX Group — Funding & Investors |url=https://www.vcbacked.co/company/sparx-group |website=VCBacked |access-date=September 30, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated